The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection

被引:50
作者
Grimbert, Philippe [1 ]
Mansour, Hicham
Desvaux, D.
Roudot-Thoraval, Francoise
Audard, Vincent
Dahan, Karine
Berrehar, Francois
Dehoulle-Poillet, Catherine
Farcet, Jean Pierre
Lang, Philippe
Le Gouvello, Sabine
机构
[1] Hop Henri Mondor, APHP, Nephrol & Transplantat Dept, Serv Nephrol, F-94010 Creteil, France
[2] Hop Henri Mondor, APHP, Immunol Lab, F-94010 Creteil, France
[3] Hop Henri Mondor, APHP, Dept Pathol, F-94010 Creteil, France
[4] Hop Henri Mondor, APHP, Dept Publ Hlth, F-94010 Creteil, France
[5] Univ Paris 12, Hop Henri Mondor, APHP, F-94010 Creteil, France
关键词
renal transplantation; borderline change; Foxp3; acute rejection;
D O I
10.1097/01.tp.0000248884.71946.19
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
The interpretation of cellular infiltrate from renal transplant recipients with borderline (BL) changes is still a challenging problem. To analyze the immune phenotype of such infiltrate, we quantified the mRNA expression of Foxp3 and interleukinL-10 and granzyme B (GB) in 15 kidney biopsies with BL changes. Controls were patients presenting type IA acute rejection and nonrejecting patients. Only levels of GB mRNA correlated significantly with response to antirejection therapy. Levels of Foxp3 mRNA in BL changes were intermediate between type IA acute rejection and nonrejecting controls. To determine the balance of alloagressive to graft-protecting T cells, we quantified the Foxp3/GB ratio. BL changes T cells infiltrate expressed a significantly higher Foxp3/GB ratio than that in IA acute rejection. These results suggest that T cell infiltrate from BL change exhibit a tolerogenic rather than a cytotoxic phenotype.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 19 条
[1]
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[2]
Molecular diagnosis of renal-allograft rejection: Correlation with histopathologic evaluation and antirejection-therapy resistance [J].
Desvaux, D ;
Schwarzinger, M ;
Pastural, M ;
Baron, C ;
Abtahi, M ;
Berrehar, F ;
Lim, A ;
Lang, P ;
le Gouvello, S .
TRANSPLANTATION, 2004, 78 (05) :647-653
[3]
A UK-wide trial of the Banff classification of renal transplant pathology in routine diagnostic practice [J].
Furness, PN ;
Kirkpatrick, U ;
Taub, N ;
Davies, DR ;
Solez, K .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (05) :995-1000
[4]
Identification of regulatory T cells in tolerated allografts [J].
Graca, L ;
Cobbold, SP ;
Waldmann, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (12) :1641-1646
[5]
Cytokines and chemokine gene expression in human kidney transplantation [J].
Hribova, P ;
Kotsch, K ;
Brabcova, I ;
Vitko, S ;
Volk, HD ;
Lacha, J .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) :760-763
[6]
The regulatory T cell family: Distinct subsets and their interrelations [J].
Jonuleit, H ;
Schmitt, E .
JOURNAL OF IMMUNOLOGY, 2003, 171 (12) :6323-6327
[7]
Intragraft mRNA expression of cytokines and growth factors in human kidney allograft biopsies by in situ RT-PCR analysis [J].
Kaminska, D ;
Tyran, B ;
Mazanowska, O ;
Letachowicz, W ;
Kochman, A ;
Rabczynski, J ;
Szyber, P ;
Patrzalek, D ;
Chudoba, P ;
Klinger, M .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) :767-769
[8]
Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance [J].
Louis, S ;
Braudeau, C ;
Giral, M ;
Dupont, A ;
Moizant, F ;
Robillard, N ;
Moreau, A ;
Soulillou, JP ;
Brouard, S .
TRANSPLANTATION, 2006, 81 (03) :398-407
[9]
Meehan SM, 1999, J AM SOC NEPHROL, V10, P1806
[10]
Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy [J].
Mesel-Lemoine, M ;
Cherai, M ;
Le Gouvello, S ;
Guillot, M ;
Leclercq, V ;
Klatzmann, D ;
Thomas-Vaslin, V ;
Lemoine, FM .
BLOOD, 2006, 107 (01) :381-388